**Description**

**A COMPOSITION FOR THE SYMPTOMATIC TREATMENT OF ARTHROSIS**

**Technical Field**

The invention relates to a composition formed for the symptomatic treatment of arthrosis.

**State of the Art**

Arthrosis is a chronic disease that occurs in one or more joints and causes specific tissue destruction in the cartilage surrounding the joint. The disease also damages the bones in the joint. Arthrosis may briefly be defined as the joint wear or aging. In addition to this natural arthrosis occurring in advanced ages, there is also the early age arthrosis observed during the local or systemic diseases associated with the joints.

Moreover, arthrosis is a disease causing the tissue destruction. It has no relation at all with arthritis deformans. Arthritis deformans, or chronic primary polyarthritis, is a disease affecting all the joints and the tissues in the joint space. Acute arthritis should also be distinguished from the arthrosis. Acute arthritis is the inflammation of the joint caused by the microbial factors. The joint rheumatism is the inflammatory response of the joint tissue to the toxins of the beta-hemolytic streptococci that are frequently observed in the young individuals and that cause the throat infections. Arthrosis, considered to be a typical disease for the advanced ages, is common in the developed countries and in the age group older than 40 years. It is more frequently seen in the women. It primarily emerges in the joints that intensively work, that are movable and/or the joints that bear the weight of the body, such as the backbone (particularly the waist and neck regions), hip, knee, foot, thumb wrist-metacarpus joint (joint at the root of the thumb).

According to the state of the art, the invention no. EP1300411B1 with classification “C07H 3/04” entitled “Novel disaccharides with anti-arthritic action” relates to the novel disaccharides of formula (l) with anti-arthritic properties, the solvates and the pharmaceutically acceptable salts thereof and the pharmaceutical compositions comprising the same.

Further, the invention no. EP1853279B1 entitled “Amide derivatives of hyaluronic acid in osteoarthrosis” concerns a biomaterial made of hexadecylamides of hyaluronic acid (HA), particularly the hexadecylamide of HA, administered by the intra-articular route as a partial/total substitute for synovial fluid to treat joints affected by osteoarthrosis (OA) as well as cases of joint inflammation and/or trauma that cause damage to the cartilage and/or synovia (associated with pain). Lastly, described and claimed is their use in the treatment of joints where the entire structure shows signs of wear due to physiological aging.

Further, according to the invention no. EP1594520B1 entitled “Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis”, peptides that have a bradykinin-antagonistic effect are suitable for the production of drugs for use in the prophylaxis and therapy of diseases whose progression is associated with an increased activity of matrix metalloproteinases. These diseases include degenerative articular diseases, for example osteoarthrosis, spondylosis and chondroporosis after joint trauma or prolonged joint immobilization after meniscus or patella injuries or ruptures of a ligament.

As a result, the presence of the need for a composition for the symptomatic treatment of arthrosis and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to reduce the tnf-alpha level.

Another object of the invention is to reduce the cox-2 level.

Another object of the invention is to support the beta-endorphine production.

Another object of the invention is to reduce the pge-2 level.

Another object of the invention is to suppress the nf-kappaB expression.

In order to achieve the aforesaid advantages, the invention is a composition for the symptomatic treatment of arthrosis, said composition being obtained by the components selected from the group comprising 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 3,5-triethyl-2,6-octadienyl]-2,4-trimethoxycafeoil]-6-(7-dihydroxyphenyl)-3-propen-4-one, 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a composition formed for the symptomatic treatment of arthrosis. The composition according to the invention reduces the tnf-alpha level, reduces the cox-2 level, supports the beta-endorphine production, reduces the pge-2 level and suppresses the nf-kappaB expression.

The composition according to the invention contains 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 3,5-triethyl-2,6-octadienyl]-2,4-trimethoxycafeoil]-6-(7-dihydroxyphenyl)-3-propen-4-one, 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one.

Said composition is obtained by a mixture of the aforesaid components according to the following ratios by weight:

30-20% 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one,

40-10% 3,5-triethyl-2,6-octadienyl]-2,4-trimethoxycafeoil]-6-(7-dihydroxyphenyl)-3-propen-4-one,

30-70% 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for the symptomatic treatment of arthrosis and the manufacture thereof for this purpose.

**CLAIMS**

1. A composition for the symptomatic treatment of arthrosis, said composition being obtained by the components selected from the group comprising 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 3,5-triethyl-2,6-octadienyl]-2,4-trimethoxycafeoil]-6-(7-dihydroxyphenyl)-3-propen-4-one, 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 30-20% by weight 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one.
3. A composition according to Claim 1 characterized in that it comprises 40-10% by weight 3,5-triethyl-2,6-octadienyl]-2,4-trimethoxycafeoil]-6-(7-dihydroxyphenyl)-3-propen-4-one.
4. A composition according to Claim 1 characterized in that it comprises 30-70% by weight 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one.
5. Use of the components according to Claims 1 to 4 obtained individually or in combinations from the group consisting of 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 3,5-triethyl-2,6-octadienyl]-2,4-trimethoxycafeoil]-6-(7-dihydroxyphenyl)-3-propen-4-one, 3,5-bis(3-methoxyethyl)-6-0-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one **for the manufacture of a composition for the symptomatic treatment of arthrosis.**

**ABSTRACT**

**A COMPOSITION FOR THE SYMPTOMATIC TREATMENT OF ARTHROSIS**

The invention relates to a composition formed for the symptomatic treatment of arthrosis.

No figure.